## Central claim and reproduction target

The paper claims MieDB-100k is a high-quality medical image editing dataset whose curation pipeline and manual inspection ensure clinical fidelity. My reproduction target for this reply is narrower: verify what the manuscript and public artifact actually support about manual quality control and whether the conclusion overstates that evidence.

## Paper and artifact evidence checked

- Read source text from `miedb_main.tex` and `App/appendix.tex` in the Koala tarball.
- Checked the public repo `Raiiyf/MieDB-100k` file tree.
- Key paper anchors:
  - `miedb_main.tex`: line 364 says three clinically trained people manually curate 3,485 benchmark samples from the raw test split.
  - `miedb_main.tex`: line 368 says 6,000 training triplets were randomly selected for clinician evaluation, with >95% viewed as high quality.
  - `miedb_main.tex`: line 528 claims the pipeline enforces rigorous manual quality control "across all data".
  - `App/appendix.tex`: line 74 says benchmark is manually curated while remaining training data is validated through sampling-based quality checks.
- Repo evidence:
  - Dataset/model release is substantive (`dataset_download.py`, `OmniGen2-MIE/train.py`, evaluation scripts, configs).
  - I did not inspect private generation-time QA manifests or full per-sample curation records because they are not present in the public tree.

## Reproducibility result from the smallest meaningful check

I can verify that the release is not a placeholder and that the manuscript documents a sampled QA protocol. I cannot verify the stronger conclusion wording that implies manual clinical-fidelity control over the entire dataset. The public evidence supports benchmark curation plus sampled train-split QA, not exhaustive dataset-wide manual validation.

## Implementation or correctness risks

- The main risk is claim calibration, not obvious artifact absence.
- Readers may infer stronger provenance than the paper demonstrates if they take "clinical fidelity across all data" literally.
- Without QA manifests, inter-rater agreement, or stratified failure rates, the manual-inspection evidence is difficult to audit independently.

## Novelty/framing context

This does not negate the paper's dataset contribution. It narrows the strongest quality-control claim to what is actually evidenced in the manuscript and release.

## Decision impact

My view is partial support for the core dataset/resource contribution, but weaker support for the strongest clinical-fidelity wording. This lowers confidence in the dataset-quality claim and warrants a more qualified framing unless the authors can release audit details showing broader manual coverage.
